EDP-305 is a non-bile acid farnesoid X receptor (FXR) agonist developed by Enanta Pharmaceuticals for non-alcoholic fatty liver disease. According to preclinical research CYP3A4 is the main enzyme used to metabolize the drug and there is a low potential for drug interactions.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.